Day One Biopharmaceuticals Inc Aktie News

Day One Biopharmaceuticals, Inc. is gaining momentum after Ojemda's strong Q3 launch, with revenues up 15% sequentially and full-year guidance raised to $145–$150m. DAWN's Ojemda is the only therapy specifically approved for PLGG, with a chance to become standard of care and ongoing Phase 3 front-line study. Strategic moves include acquiring Mersana Therapeutics for ADC pipeline expansion and a...

BRISBANE, Calif., Dec. 16, 2025 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals, Inc. (Nasdaq: DAWN) (“Day One” or the “Company”), a biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced that Dr. Jeremy Bender, chief executive officer, will present during the 44th Annual J.P.

Updated data expands clinically meaningful results available from FIREFLY-1 pivotal trial  77% of patients who entered the treatment-free observation period following OJEMDA treatment remained off therapy for at least 12 months The median time to next treatment (TTNT) following initiation of OJEMDA exceeded 3.5 years    BRISBANE, Calif., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Day One Biopharmaceutic...

BRISBANE, Calif., Nov. 18, 2025 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals, Inc. (Nasdaq: DAWN) (“Day One” or the “Company”), a biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced that management will participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conferenc...

Acquisition expands Day One's portfolio with novel antibody-drug conjugate (ADC) emiltatug ledadotin (Emi-Le) Emi-Le has demonstrated early anti-tumor activity in an ongoing Phase 1 study for adenoid cystic carcinoma type-1 (ACC-1), a cancer with high unmet need and a lack of therapeutic options Day One will apply existing scientific and commercial capabilities to this investigational innovativ...

Three-year follow-up data from FIREFLY-1 demonstrates durable responses with evidence of clinical stability off treatment, with the potential for retreatment after progression Treatment-free interval data to also be disclosed for the first time BRISBANE, Calif., Nov. 10, 2025 (GLOBE NEWSWIRE) --  Day One Biopharmaceuticals, Inc. (Nasdaq: DAWN) (“Day One” or the “Company”), a biopharmaceutical c...

Day One Biopharmaceuticals, Inc. ( DAWN ) Q3 2025 Earnings Call November 4, 2025 4:30 PM EST Company Participants Joey Perrone - Senior Vice President of Finance & Investor Relations Jeremy Bender - CEO, President & Director Lauren Merendino - Chief Commercial Officer Charles York - COO & CFO Michael Vasconcelles - Head of Research & Development Conference Call Participants Tara Bancroft - TD C...

Commercial execution delivers best quarter launch-to-date with growth across all dimensions of core business Raising OJEMDA full-year 2025 net product revenue guidance to $145 to $150 million Three-year FIREFLY-1 data to be released in oral presentation at Society for Neuro-Oncology on Nov. 23, 2025 Ended the third quarter with $451.6 million in cash, cash equivalents and short-term investments...